A5108116814- Particle physics theoretical and experimental studies
- High-Energy Particle Collisions Research
- Particle Detector Development and Performance
- Quantum Chromodynamics and Particle Interactions
- Dark Matter and Cosmic Phenomena
- Neutrino Physics Research
- Cosmology and Gravitation Theories
- Computational Physics and Python Applications
- Distributed and Parallel Computing Systems
- Radiation Detection and Scintillator Technologies
- Pharmacovigilance and Adverse Drug Reactions
- Black Holes and Theoretical Physics
- Astrophysics and Cosmic Phenomena
- Medical Imaging Techniques and Applications
- Sirtuins and Resveratrol in Medicine
- Pharmaceutical studies and practices
- Tuberculosis Research and Epidemiology
- Antiplatelet Therapy and Cardiovascular Diseases
- Particle Accelerators and Free-Electron Lasers
- 3D Printing in Biomedical Research
- Adipose Tissue and Metabolism
- Image and Signal Denoising Methods
- Ultrasound Imaging and Elastography
- Big Data Technologies and Applications
- Advanced MRI Techniques and Applications
Guangdong Medical College
2024-2025
Dongguan People’s Hospital
2024-2025
University of Science and Technology of China
2018-2024
A. Alikhanyan National Laboratory
2024
The University of Adelaide
2018-2023
Petersburg Nuclear Physics Institute
2011
University of Washington
2011
Background Celecoxib is now clinically recognized as a candidate for treating various neurological disorders and cancers. The recent emergence of some serious adverse reactions concerning.
To assess lurasidone's real-world safety via retrospective analysis of post-marketing adverse reactions. Signal mining was carried out by retrieving the event reports (AEs) associated with lurasidone from FDA Adverse Event Reporting System (FAERS) database spanning first quarter 2011 to fourth 2023. Disproportionality analyses including Odds Ratio (ROR), Proportional (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and empirical geometric mean (EBGM) were used presence...
In recent years, β-blockers such as metoprolol have been upgraded to first-line antihypertensive drugs. However, demonstrates poor prognosis effects on diseases stroke. Further clinical application may expand the possibility of its related adverse reactions. Currently, there is a lack comprehensive research overall safety metoprolol.
Background Based on real data from the FDA Adverse Event Reporting System (FAERS), we explored and evaluated adverse reactions (ADRs) of sulfasalazine (SSZ) in first quarter 2004-2023 to provide a reference basis early warning for safe use SSZ clinic.